Global Breast Cancer Drugs Market Is Expected To Reach Around USD 669.37 Billion By 2032

Zion Market Research has published a new report titled “Breast Cancer Drugs Market By Drug Type (Chemotherapy Drugs, Hormone Therapy Drugs, Targeted Therapy Drugs, and Other Therapeutic Drugs), and  Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024 - 2032”. According to the report, the global breast cancer drugs market was valued at USD 44.17 billion in 2023 and is expected to reach USD 669.37 billion by the end of 2032 with a 35.30% CAGR from 2024 to 2032.

Breast cancer is the result of uncontrolled cell division of breast cells, most commonly cells of breast lobule and ducts. It may also affect fatty or connective tissues within the breasts. Breast cancer is the second most common type of cancer worldwide, affecting nearly 2 million women.

Browse the full “Breast Cancer Drugs Market By Drug Type (Chemotherapy Drugs, Hormone Therapy Drugs, Targeted Therapy Drugs, and Other Therapeutic Drugs), and  Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024 - 2032” Report at https://www.zionmarketresearch.com/report/breast-cancer-drugs-market

The increasing breast cancer prevalence worldwide is the major driving factor for the global breast cancer drugs market along with increasing health awareness, healthcare spending, and rising disposable income of people. Investments made by major market players for novel drug development and favorable reimbursement policies are also contributing to the breast cancer drugs market globally. Additionally, government funding/grants for research and development and patent expiry will further propel this market’s growth in the future. However, the high cost of treatment may hamper the breast cancer drugs market growth.

The global breast cancer drugs market segments are based on drug type and region. Based on drug type, the market is segmented into chemotherapy drugs, hormone therapy drugs, targeted therapy drugs, and other therapeutic drugs. Chemotherapy drugs held the largest market share in 2023, whereas targeted therapy drugs are expected to show the highest CAGR over the forecast time period. Targeted therapy helps the immune system destroy cancer cells by interfering with specific proteins and fights the cancer cells only along with having fewer side effects as compared to chemotherapeutic drugs. This will fuel the targeted therapy drugs’ market popularity over the estimated timeframe.

Chemotherapy drugs are sub-segmented into anthracyclines, taxanes, antimetabolites, alkylating agents, and epothilones. Anthracyclines segment is split into doxorubicin and epirubicin. Taxanes are split into paclitaxel and docetaxel. Antimetabolites segment is classified into fluorouracil, capecitabine, and gemcitabine. Hormone therapy drugs are classified into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and other hormonal therapies. Selective estrogen-receptor modulators segment is further split into tamoxifen, raloxifene, and toremifene. Aromatase inhibitors segment is split into letrozole, anastrozole, and megestrol. Other hormonal therapy drugs include goserelin acetate, fulvestrant, fluoxymesterone etc. The targeted therapy drugs are classified into monoclonal antibodies (mAbs) and tyrosine kinase inhibitors. Monoclonal antibodies (mAbs) are further split into bevacizumab, trastuzumab, and other mAbs.

By region, North America dominated the global breast cancer drugs market with a market share of about 48.2% in 2023 and is projected to retain its leading position over the forecast time period as well. This can be attributed to the increasing prevalence of breast cancer, growing health awareness, the presence of key market players in the region, ongoing drug discovery research and development projects, favorable reimbursement policies for breast cancer, increasing use of breast cancer targeted therapies as precision medicine, and presence of developed healthcare infrastructure. Europe held the second largest market share in 2023 of the global breast cancer drugs market, owing to the growing adoption of targeted therapies, increasing breast cancer prevalence, favorable reimbursement policies, and developed healthcare infrastructure. Asia Pacific is projected to witness the highest CAGR over the forecast period in the global breast cancer drugs market, due to the growing health awareness, increasing disposable income, and rising healthcare spending, increasing breast cancer burden.

Some key players of the global breast cancer drugs market include AbbVie, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Celgene Corporation, Eli Lilly and Company, Merck & Co., Inc., Biocon, Genzyme Corporation, MacroGenics, Inc., Janssen Global Services LLC, Onyx Pharmaceuticals Inc., Celldex Therapeutics, and BioNumerik Pharmaceuticals, Inc.

This report segments the global breast cancer drugs market into:

Global Breast Cancer Drugs Market: By Drug Type

• Chemotherapy Drugs
  • Anthracyclines
    • Doxorubicin
    • Epirubicin
  • Taxanes
    • Paclitaxel
    • Docetaxel
  • Antimetabolites
    • Fluorouracil
    • Capecitabine
    • Gemcitabine
  • Alkylating Agents 
  • Epothilones
• Hormone Therapy Drugs
  • Selective Estrogen-Receptor Modulators (SERMs)
    • Tamoxifen
    • Raloxifene
    • Toremifene
  • Aromatase Inhibitors
    • Letrozole
    • Anastrozole
    • Megestrol
  • Other Hormonal Therapies
    • Goserelin acetate
    • Fulvestrant
    • Fluoxymesterone
• Targeted Therapy Drugs
  • Monoclonal Antibodies (mAbs)
    • Bevacizumab
    • Trastuzumab
    • Other mAbs
  • Tyrosine kinase inhibitors
• Other Therapeutic Drugs

Global Breast Cancer Drugs Market: By Region

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com